COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study

Bratisl Lek Listy. 2022;123(2):120-124. doi: 10.4149/BLL_2022_018.

Abstract

Background: Aim of this study is to investigate COVID-19 outcomes in patients with antiphospholipid syndrome (APS).

Methods: A retrospective cohort was formed from APS patients. Patients were screened for a record of positive SARS-CoV 2 PCR. In PCR‑positive patients, clinical data and information regarding COVID-19 outcomes were collected from medical records.

Results: A positive PCR test was detected in 9/53 APS patients, while 66.7 %, 33.3 % and 11.1 % of APS patients with COVID-19 were under hydroxychloroquine, LMWH or warfarin, and acetylsalicylic acid, respectively. There were 3/9 patients found to be hospitalized and one died. No new thrombotic event was reported in any of the patients during COVID-19 infection.

Conclusion: Baseline use of hydroxychloroquine, antiaggregants and anticoagulants may be associated with an absence of new thrombotic event (Tab. 2, Ref. 33).

Keywords: COVID-19; antiphospholipid syndrome; outcome; thrombosis mortality..

MeSH terms

  • Antibodies, Antiphospholipid
  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome* / complications
  • COVID-19*
  • Heparin, Low-Molecular-Weight
  • Humans
  • Retrospective Studies
  • SARS-CoV-2

Substances

  • Antibodies, Antiphospholipid
  • Anticoagulants
  • Heparin, Low-Molecular-Weight